Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
- Registration Number
- NCT06813365
- Lead Sponsor
- Dizal Pharmaceuticals
- Brief Summary
This study is designed to evaluate safety and antitumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations. This is the first time the drug is tested in human.
- Detailed Description
The study includes two parts: Part A (dose escalation) and Part B(dose expansion). In Part A, locally advanced or metastatic NSCLC patients with EGFR sensitizing mutations (Exon19del and/or L858R) following at least 1 prior EGFR TKI regimen and platinum-containing chemotherapy will be enrolled. In Part B, locally advanced or metastatic NSCLC patients with EGFR sensitizing mutations following at least 1 prior EGFR TKI treatment and harboring C797X mutation will be enrolled.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 76
- Patients must be able to provide documented informed consent.
- Aged ≥ 18 years.
- Histologically or cytologically confirmed diagnosis of NSCLC, locally advanced or metastatic, not suitable for curative therapy.
- Documentation of EGFR mutation from a local CLIA-certified laboratory (or equivalent). Part A: EGFR sensitizing mutation (Exon19del and/or L858R). Part B: EGFR sensitizing mutation (Exon19del and/or L858R) and C797X mutation.
- Provide adequate amount of pretreatment tumor samples collected after disease progression on the last EGFR TKI treatment.
- Failed (progressed or are intolerant) at least 1 prior EGFR TKI regimen. Patients enrolled in Part A will be required to have progressed or become intolerant after adequate treatment with at least one-line EGFR TKI and platinum-containing chemotherapy.
- ECOG 0 or 1 with predicted life expectancy ≥ 12 weeks.
- Patients with brain metastases must have a stable BM status.
- Measurable disease per RECIST 1.1.
- Adequate hematopoietic and other organ system functions.
- Male Patients with female partners of childbearing potential should use barrier contraceptives and refrain from donating sperm during their participation in this study and for 3 months following the last dose of the study drug.
- Carry any other known EGFR alterations, including but not limited to uncommon EGFR mutations (G719X, S768I, L861Q, exon 20 insertions, etc.)(Part B).
- NSCLC with mixed small cell lung cancer (SCLC) or NSCLC with histologic SCLC transformation.
- Prior treatment with any of the following:1)Immunotherapy or other antibody therapy within 4 weeks prior to the first administration;2)Any cytotoxic chemotherapy, investigational drugs or other anticancer drugs from a previous treatment regimen or clinical study within 14 days prior to the first administration;3)Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose, radiation to more than 30% of the bone marrow or with a wide field of radiation within 28 days before screening;4)Currently receiving or unable to stop drug or herbal supplements known to be potent inhibitors or inducers of cytochrome P450 (CYP)3A4. A washout period of at least 2 weeks for strong inhibitors and 3 weeks for strong inducers is required prior to the first study drug administration.5)currently receiving or unable to stop drugs known to be CYP3A4 sensitive substrate with a narrow therapeutic index. A washout period of at least 14 days is required prior to the first study drug administration;6)currently receiving or unable to stop drugs known to be proton pump inhibitors. A washout period of at least 7 days is required prior to the first study drug administration;7)Major surgery within 4 weeks of the first administration of DZD6008 or anticipated during the study period.
- Any unresolved toxicities from prior anti-cancer therapy greater than CTCAE Grade 1.
- Spinal cord compression or leptomeningeal metastasis.
- Patients with any other malignancy within 2 years of the first administration of study drug.
- Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses as judged by investigator.
- Patients with active infection including but not limited to HBV, HCV, HIV and active infection of COVID-19.
- Resting QTcF > 470 msec; Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG;Any factors that increase the risk of QTc prolongation.
- Past medical history of ILD or active ILD.
- Diseases which would preclude adequate absorption of DZD6008.
- Received a live vaccine within 2 weeks before the first administration of DZD6008.
- Women who are pregnant or breastfeeding.
- Hypersensitivity to active or inactive excipients of DZD6008.
- Involvement in the planning and conduct of the study.
- Judgment by the investigator that the patients is unlikely to comply with study procedures
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Part A Dose Escalation cohorts (20 mg once daily [QD]) DZD6008 - Part A Dose Escalation cohorts (40 mg QD) DZD6008 - Part A Dose Escalation cohorts (60 mg QD) DZD6008 - Part A Dose Escalation cohorts (90 mg QD) DZD6008 - Part A Dose Escalation cohorts (120 mg QD) DZD6008 - Part B Dose Expansion cohorts (selected dose 2 QD) DZD6008 - Part B Dose Expansion cohorts (selected dose 1 QD) DZD6008 - Part A Dose Escalation cohorts (150 mg QD) DZD6008 - Food effect cohort (selected dose 1) DZD6008 - Food effect cohort (selected dose 2) DZD6008 -
- Primary Outcome Measures
Name Time Method Part A: To assess safety and tolerability Through the study completion, an average of around 1 year. Number of participants with Adverse events (AEs)/Serious adverse events (SAEs)
Part B: To assess anti-tumor activity Through the study completion, an average of around 1 year. Objective Response Rate (ORR) as assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Secondary Outcome Measures
Name Time Method Part B: To assess the preliminary anti-tumor activity Through the study completion, an average of around 1 year. Progression PFS as assessed by IRC and investigators per RECIST version 1.1.
Part B: Plasma concentration of DZD6008 From first dosing to cycle 11 day 1, each cycle is 21 days. Total concentrations of DZD6008 in plasma.
Part B: To assess safety and tolerability Through the study completion, an average of around 1 year. Number of participants with Adverse events (AEs)/Serious adverse events (SAEs)
Part A: To characterize the plasma concentration of DZD6008 following single and multiple oral dose administration From first dosing to cycle 7 day 1, each cycle is 21 days. Total concentrations of DZD6008 in plasma.
Part A: To assess the urine concentration of DZD6008 At the first day of cycle 2 (each cycle is 21 days). Total concentrations of DZD6008 in urine.
Part A: To assess cerebrospinal fluid of DZD6008 in participants with brain metastasis at baseline Cycle 1 day 15. Total concentrations of DZD6008 in cerebrospinal fluid
Part A: To assess the effect of low-fat food on the plasma concentration of DZD6008 The first dosing day on cycle 0 (cycle 0 is 3 days). Total concentrations of DZD6008 in plasma.
Part A: To assess the anti-tumor activity Through the study completion, an average of around 1 year. Progression Free Survival (PFS) as assessed by investigators per RECIST version 1.1.
Part B: To assess the anti-tumor activity Through the study completion, an average of around 1 year. Progression DoR as assessed by IRC and investigators per RECIST version 1.1.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Peking Union Medical College Hospital
🇨🇳Beijing, Beijing, China